

To: CN=Robert W Baker/OU=AM/O=LLY@Lilly; CN=Margaret O Sowell/OU=AM/O=LLY@Lilly
Date: 06/15/2002 08:39:50 AM
From: CN=Dennis G West/OU=AM/O=LLY
Subject: Re: FYI diabetes/Newcomer

Just to keep the two of you informed regarding current status of Newcomer. I understand Missy that your plans are changing. Is it still possible for you to be available in July to meet with Newcomer in St. Louis? If so if you can give me several dates I will try to firm with John next week.

----- Forwarded by Dennis G West/AM/LLY on 06/15/2002 07:34 AM -----

Dennis G West

06/15/2002 07:24 AM

To: John Newcomer <newcomej@psychiatry.wustl.edu>
cc:
Subject: Re: diabetes

I totally agree John this data set as well as all other data sets to date have value points and limitations but the trend being established with all this newly generated data is that there appears to be a relationship associated with all the drugs in the "atypical" antipsychotic class. This association at some time in the future may prove to be greater numerically for one drug or the other but I do not see evidence at this time that establishes causality for olanzapine or any other compound. Hence I have difficulty seeing any atypical being classified as a second line drug over the others at this time. It would be better to assume a position, you have mentioned to me in your office, that anyone treating patients with atypicals should be aware of the potential relationship of glucose/insulin irregularities associated with these drugs and monitor appropriately.

Did you have an opportunity to check your schedule in July? I would like to solidify a date that Margaret Sowell could visit. I believe you will find it valuable for both of you to review data from each of the Euglycemic clamp studies.

Page: 1 of 1